• Six clinical trials on MSCs approved by US FDA
    Six clinical trials on MSCs approved by US FDA
  • One of the few companies manufacturing both hMSC and hNSC
    One of the few companies manufacturing both hMSC and hNSC
  • First FDA-approved clinical trial using stem cells to treat Alzheimer’s
    First FDA-approved clinical trial using stem cells to treat Alzheimer’s
  • MSCs approved as a treatment of AMI in Kazakhstan
    MSCs approved as a treatment of AMI in Kazakhstan
  • Producing clinical-grade stem cells with strong activity in large scale
    Producing clinical-grade stem cells with strong activity in large scale
  • SCF activity preserved through patented technology for 3 years
    SCF activity preserved through patented technology for 3 years

Add:21st Floor, Block 1, Jusha Center, No.16 Xinyuanli, Chaoyang District, Beijing

Phone: 86-10-64654791

 

 

Copyright ©Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.! 

京ICP备19006400号-1     Powered by 300.cn

Technology

Technology Platform

Technology Platform

Jiuzhitang Maker will bring in cutting-edge stem cell pharmaceutical technologies developed by Stemedica Cell Technologies, Inc. At present, Jiuzhitang Maker is building its 4500m2 R&D and manufacturing facility in ZCG Biomedicine Industry Park, Daxing District, Beijing. The facility will be constructed following EU cGMP standards and is estimated to
Products

Products

Ischemia-tolerant human mesenchymal stem cells (ithMSCs) have higher tolerability, activity, and post-homing repair capacity under conditions of hypoxic ischemia. Upon homing to injured body parts, ithMSCs can secret various cytokines, chemokines, anti-inflammatory factors and growth factors to rescue high-risk cells, protect healthy cells,
Intellectual property

Intellectual property

Among the 26 patents filed by Stemedica, 8 have been approved as of today. These patents seek protection for the stem cell production process and the usage of stem cells and cytokines. The confidential technologies owned by Stemedica concerning large-scale production of stem cell products are key to making stem cells into drugs.